EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non‐renal solid organ transplant recipients?

Milo Gatti iD, Matteo Rinaldi iD, Luciano Potena iD, Elena Salvaterra, Maria Cristina Morelli, Maddalena Giannella iD, Pierluigi Viale, Federico Pea

Transplant Infectious Disease · 2023

DOI: 10.1111/tid.14107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Milo Gatti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Organ Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim of this study is to explore the relationship between ganciclovir exposure and clinical efficacy and/or safety in non‐renal solid organ transplant (SOT) recipients receiving preemptive therapy with ganciclovir/valganciclovir and undergoing therapeutic drug monitoring (TDM)‐guided dosing optimization.

Methods

Non‐renal SOT recipients admitted to IRCCS Azienda Ospedaliero‐Universitaria of Bologna receiving preemptive therapy with ganciclovir or valganciclovir for active cytomegalovirus (CMV) infection and who underwent at least one TDM were included. Desired ganciclovir C min range was set at 1–3 mg/L, and average ganciclovir trough concentrations (C min ) were calculated for each patient. Reduced CMV viral load below the lower limit of quantification (LLQ) at 30 days and occurrence of myelotoxicity were selected as the primary outcome. Univariate analysis was performed by comparing patients with average C min below or above 1 or 3 mg/L. Receiver operating characteristic (ROC) curve analysis was performed to identify the average ganciclovir C min cut‐off predictive for clinical efficacy or toxicity.

Results

Twenty‐nine out of 89 retrieved patients met the inclusion criteria, with a median (interquartile [IQR]) baseline CMV viral load of 27,163 copies/mL (IQR 13 159.75–151 340.25 copies/mL). Reduced CMV viral load below the LLQ at 30 days was found in 17 patients (58.6%). No difference was found in the primary outcome between patients showing average C min below or above 1 mg/L (100.0% vs. 53.8%; p = .25) and/or 3 mg/L (65.2% vs. 33.3%; p = .20). ROC analysis did not allow to identify an average C min cut‐off predictive of clinical efficacy or toxicity.

Conclusions

No clear relationship between ganciclovir C min and neither CMV eradication nor safety issues was identified. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsOrgan TransplantationHumansGanciclovirValganciclovirAntiviral AgentsDrug MonitoringTransplant Recipients

Stichwörter der Autor:innen

ganciclovirleukopeniapreemptive therapysolid organ transplant recipientstherapeutic drug monitoringvalganciclovir

Substanzen

GanciclovirValganciclovirAntiviral Agents

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Unit of Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Division of Interventional Pulmonology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Internal Medicine Unit for the Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

ORCID-Profile: Milo Gatti, Matteo Rinaldi, Luciano Potena, Maddalena Giannella

Förderung

  • Italian Ministry of Health

Zitieren

APA

Gatti, M., Rinaldi, M., Potena, L., Salvaterra, E., Morelli, M. C., Giannella, M., Viale, P., & Pea, F. (2023). Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non‐renal solid organ transplant recipients?. Transplant Infectious Disease. https://doi.org/10.1111/tid.14107

Vancouver

Gatti M, Rinaldi M, Potena L, Salvaterra E, Morelli MC, Giannella M, et al. Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non‐renal solid organ transplant recipients?. Transplant Infectious Disease. 2023. doi:10.1111/tid.14107

BibTeX
@article{Gatti2023,
  author = {Gatti, Milo and Rinaldi, Matteo and Potena, Luciano and Salvaterra, Elena and Morelli, Maria Cristina and Giannella, Maddalena and Viale, Pierluigi and Pea, Federico},
  title = {Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non‐renal solid organ transplant recipients?},
  journal = {Transplant Infectious Disease},
  year = {2023},
  doi = {10.1111/tid.14107}
}
Kostenlos starten →